Chroma Medicine emerges with $125 million to bankroll development of epigenetic editing to create therapeutics that control gene expression. The biotech is led by former Editas Medicine and Regeneron…
Provention Bio has made three leadership hires since Nov. 5 as it awaits a Type A meeting with the FDA later this month to discuss its rejected lead drug, teplizumab, for the treatment of Type 1…
The tacked-on funds from Koch Disruptive Technologies bring Sense Biodetection’s series B haul to $65 million.
Valo Health’s merger with a Khosla Ventures SPAC has gone belly up. The partners terminated the deal, which would have left Valo with $750 million before expenses, ‘based on current market conditions,…
Swiss major Roche is cutting its losses and casting aside its COVID drug collab with biotech Atea Pharmaceuticals.
Chroma Medicine is developing epigenetic therapies that turn genes on or off. The biotech startup has emerged from stealth mode backed by a $125 million Series A round of funding.
Lizzy Feliciano A 20-year veteran of the healthcare technology industry, Lizzy brings a wealth of experience building technology and analytics brands through differentiated messaging architectures, hyper-targeted demand generation strategies, and thought leadership programs. Lizzy believes effective marketing does not only build brands and drive sales, but also transforms the trajectory of companies and markets. Most …
The company, which pulls together information on clinicians and researchers, recently closed a funding round led by Altimeter Capital. It plans to use the funds to build out more features and grow its network.
INVEST, scheduled for March 28-30, 2022 in Chicago, marks a return to in-person events for MedCity News. The conference, held in partnership with Mid-America Healthcare Investors Network, will…
The results, shared at AHA 2021, found that a third of adults who used an ECG patch after getting a heart rhythm notification from their Fitbit had atrial fibrillation. However, the study faced some…
